NCT07008547View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

March 11, 2026

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

Netakimab

Netakimab administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

SPH-BIOCAD (HK) Limited

INDUSTRY

NCT07008547 - To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter